Compounds > n-(3-aminopropyl)cyclohexylamine
Page last updated: 2024-12-06

n-(3-aminopropyl)cyclohexylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID18718
SCHEMBL ID27221
MeSH IDM0216604

Synonyms (58)

Synonym
BIO1_001426
BIO1_000448
BIO1_000937
3312-60-5
1, n-cyclohexyl-
nsc87572
1-(cyclohexylamino)-3-aminopropane
n-cyclohexylpropylene-1,3-diamine
nsc-87572
n-(3-aminopropyl)cyclohexylamine
cyclohexylamine, n-(3-aminopropyl)-
n-cyclohexyl-1,3-propanediamine
cyclohexyl-1,3-propanediamine
n-cyclohexyl-1,3-propylenediamine
3-(aminopropyl)cyclohexylamine
3-(cyclohexylamino)-1-propylamine
n-cyclohexyl-1,3-diaminopropane
PDSP1_000332
PDSP2_000330
n-cyclohexyl-1,3-propanediamine, 99%
A0891
n-cyclohexylpropylene 1,3-diamine
n'-cyclohexylpropane-1,3-diamine
AKOS000120145
1,3-propanediamine, n1-cyclohexyl-
3-cyclohexylaminopropylamine
1,3-propanediamine, n-cyclohexyl-
nsc 87572
unii-f4xob09fkn
einecs 222-001-7
f4xob09fkn ,
n1-cyclohexylpropane-1,3-diamine
cas_3312-60-5
aminopropyl-cyclohexylamine
bdbm86157
FT-0629166
3-(cyclohexylamino)propylamine
(cyclohexylamino)propylamine
n-(3-aminopropyl)-n-cyclohexylamine
3-amino-1-(cyclohexylamino)propane
n-cyclohexyltrimethylenediamine
SCHEMBL27221
n-1-cyclohexyl-propane-1,3-diamine
3-cyclohexylamino-1-propylamine
DTXSID6062969
n-cyclohexyl trimethylene diamine
n-cyclohexylpropane-1,3-diamine
mfcd00003838
J-019035
n1-cyclohexyl-1,3-propanediamine
3-aminocyclohexylaminopropane
CS-W016230
Q27277640
A875416
n-(3-aminopropyl)cyclohexylamine; n-cyclohexyl-1,3-diaminopropane~n-cyclohexyl-1,3-propanediamine
D84281
EN300-20614
HY-W015514
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (50.00)18.2507
2000's3 (30.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
putrescine
[no description available]		2.7130alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		7.6930polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		3.150polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.9240alpha-amino acid;
fluoroamino acid		trypanocidal drug
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.0510ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		1.9810L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.0210aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
thiazoles
[no description available]		2.04101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		1.9810amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0410organic bromide saltcolorimetric reagent;
dye
hypusine
hypusine: N-terminal amino alcohol deriv of Lys occurring in bovine brain & in the urine of children with familial hyperlysinemia; minor descriptor (75-82); online & Index Medicus search LYSINE/AA (75-82). hypusine : An L-lysine derivative that is L-lysine bearing a (2R)-4-amino-2-hydroxybutyl substituent at position N(6).		2.0210
trans-4-methylcyclohexylamine
[no description available]		2.9140amine
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.05103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
cucurbit(8)uril
cucurbit(8)uril: a macrocyclic polymer compound comprising 8 GLYCOLURIL units with methylene bridges		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9810
Experimental Mammary Neoplasms
[description not available]		01.9810
Experimental Hepatoma
[description not available]		01.9810
Breast Cancer
[description not available]		01.9810
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9810
Absence Seizure
[description not available]		01.9810
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9810